目的:比较一期腹腔镜胆囊切除(LC)联合胆总管探查取石(LCBDE)与分期内镜取石(ERCP)和LC治疗胆囊结石合并胆总管结石的临床效果。方法:回顾性分析2013年1月—2014年6月在西安交通大学第一附属医院行微创治疗的112例胆囊结石合并胆总管结...目的:比较一期腹腔镜胆囊切除(LC)联合胆总管探查取石(LCBDE)与分期内镜取石(ERCP)和LC治疗胆囊结石合并胆总管结石的临床效果。方法:回顾性分析2013年1月—2014年6月在西安交通大学第一附属医院行微创治疗的112例胆囊结石合并胆总管结石患者资料,其中52例行一期LC+LCBDE(LCBDE组),60例行ERCP后24 h或择期行LC(ERCP组),比较两组相关临床指标。结果:除LCBDE组平均年龄小于ERCP组外(42.4岁vs.57.4岁,P<0.05),两组其余一般资料均具有可比性。两组均无死亡病例,手术成功率(94.3%vs.98.4%)、总并发症发生率(8.2%vs.10.1%)、结石残余发生率(2.0%vs.1.7%)等差异均无统计学意义(P>0.05);ERCP组术后高淀粉酶血症发生率明显高于LCBDE组(16.9%vs.4.1%,P<0.05),但均为单纯性淀粉酶升高;与ERCP组比较,LCBDE组术后住院时间更短(4.9 d vs.6.3 d),总住院费用减少(21 685.9元vs.30 354.3元),但LCBDE组手术时间明显延长(117.1 min vs.97.4 min)(均P<0.05)。结论:一期LC+LCBDE或分期ERCP+LC治疗胆囊结石合并胆总管结石均安全、有效,可根据患者情况选择应用。展开更多
该指南由欧洲消化内镜学会(ESGE)制订,就如何处理胆总管结石(common bile duct stones, CBDS)提供了切实可行的建议。它包括疑似CBDS患者的诊断策略以及不同CBDS的治疗方案。主要推荐要点如下。1CBDS的流行病学、自然病史和处理推荐胆...该指南由欧洲消化内镜学会(ESGE)制订,就如何处理胆总管结石(common bile duct stones, CBDS)提供了切实可行的建议。它包括疑似CBDS患者的诊断策略以及不同CBDS的治疗方案。主要推荐要点如下。1CBDS的流行病学、自然病史和处理推荐胆囊结石在发达国家患病率达10%~15%,累积年发病率为0.60%。在有症状的胆囊结石患者中CBDS的患病率为8%~18%,但尚无无症状胆囊结石患者中CBDS的流行病学数据。ESGE建议:推荐所有CBDS患者,只要能耐受手术治疗,无论有无症状,均取石治疗。(强烈推荐,低质量证据)CBDS的自然病史尚不清楚。展开更多
Background Post-endoscopic retrograde cholangiopancreatography pancreatitis （PEP） is regarded as one of the worrisome complications of endoscopic retrograde cholangiopancreatography （ERCP）. Results of randomized c...Background Post-endoscopic retrograde cholangiopancreatography pancreatitis （PEP） is regarded as one of the worrisome complications of endoscopic retrograde cholangiopancreatography （ERCP）. Results of randomized controlled trials evaluating the preventive effect of ulinastatin and gabexate mesylate （GM） on PEP are contradictory. The present study was designed to evaluate the prophylactic effect of ulinastatin and GM on PEP with meta-analyses of randomized controlled trials （RCTs）. Methods Five electronic databases were searched for RCTs evaluating the preventive effect of ulinastatin and GM on PEP. Summary effects were assessed with the methods recommended by the Cochrane Collaboration. Results Twelve studies involving 5105 participants were included in our meta-analyses. Administration of ulinastatin decreased the incidence of PEP only at sufficient doses （OR, 0.39; 95% C/, 0.19 to 0.81; P=0.01）. Number needed to treat （NNT） was 6. And administration of ulinastatin also reduced the incidence of post-ERCP hyperamylasemia （PEHA） （OR, 0.40; 95% C/, 0.28 to 0.58; P〈0.000 01）. Slow infusion of high-dose GM was effective for PEP prevention （OR, 0.44; 95% Cl, 0.25 to 0.79; P=0.006）, and rapid infusion of low-dose GM also showed efficacy for PEP prophylaxis （OR, 0.37; 95% C/, 0.20 to 0.69; P=0.002）. NNT was 7 and 6 respectively. However, administration of GM at low doses and by slow infusions was ineffective （OR, 0.99; 95% Cl, 0.64 to 1.55; P=0.98）. Administration of GM had the tendency to reduce PEHA rate, but not to a statistical significance （OR, 0.86; 95% CI, 0.73 to 1.01; P=0.06）. When low-quality studies were excluded, the meta-analysis with two high-quality studies indicated that ulinastatin did not reduce the rate of PEP （OR, 0.63; 95% Cl, 0.32 to 1.26; P=0.19） and PEHA incidence （OR, 0.80; 95% Cl, 0.31 to 2.07; P=0.64）. The meta-analysis with six high-quality studies showed that GM administration decreased PEP incidence （OR, 0.52; 95% CI, 0.29 to 0.91;展开更多
文摘目的:比较一期腹腔镜胆囊切除(LC)联合胆总管探查取石(LCBDE)与分期内镜取石(ERCP)和LC治疗胆囊结石合并胆总管结石的临床效果。方法:回顾性分析2013年1月—2014年6月在西安交通大学第一附属医院行微创治疗的112例胆囊结石合并胆总管结石患者资料,其中52例行一期LC+LCBDE(LCBDE组),60例行ERCP后24 h或择期行LC(ERCP组),比较两组相关临床指标。结果:除LCBDE组平均年龄小于ERCP组外(42.4岁vs.57.4岁,P<0.05),两组其余一般资料均具有可比性。两组均无死亡病例,手术成功率(94.3%vs.98.4%)、总并发症发生率(8.2%vs.10.1%)、结石残余发生率(2.0%vs.1.7%)等差异均无统计学意义(P>0.05);ERCP组术后高淀粉酶血症发生率明显高于LCBDE组(16.9%vs.4.1%,P<0.05),但均为单纯性淀粉酶升高;与ERCP组比较,LCBDE组术后住院时间更短(4.9 d vs.6.3 d),总住院费用减少(21 685.9元vs.30 354.3元),但LCBDE组手术时间明显延长(117.1 min vs.97.4 min)(均P<0.05)。结论:一期LC+LCBDE或分期ERCP+LC治疗胆囊结石合并胆总管结石均安全、有效,可根据患者情况选择应用。
文摘该指南由欧洲消化内镜学会(ESGE)制订,就如何处理胆总管结石(common bile duct stones, CBDS)提供了切实可行的建议。它包括疑似CBDS患者的诊断策略以及不同CBDS的治疗方案。主要推荐要点如下。1CBDS的流行病学、自然病史和处理推荐胆囊结石在发达国家患病率达10%~15%,累积年发病率为0.60%。在有症状的胆囊结石患者中CBDS的患病率为8%~18%,但尚无无症状胆囊结石患者中CBDS的流行病学数据。ESGE建议:推荐所有CBDS患者,只要能耐受手术治疗,无论有无症状,均取石治疗。(强烈推荐,低质量证据)CBDS的自然病史尚不清楚。
文摘Background Post-endoscopic retrograde cholangiopancreatography pancreatitis （PEP） is regarded as one of the worrisome complications of endoscopic retrograde cholangiopancreatography （ERCP）. Results of randomized controlled trials evaluating the preventive effect of ulinastatin and gabexate mesylate （GM） on PEP are contradictory. The present study was designed to evaluate the prophylactic effect of ulinastatin and GM on PEP with meta-analyses of randomized controlled trials （RCTs）. Methods Five electronic databases were searched for RCTs evaluating the preventive effect of ulinastatin and GM on PEP. Summary effects were assessed with the methods recommended by the Cochrane Collaboration. Results Twelve studies involving 5105 participants were included in our meta-analyses. Administration of ulinastatin decreased the incidence of PEP only at sufficient doses （OR, 0.39; 95% C/, 0.19 to 0.81; P=0.01）. Number needed to treat （NNT） was 6. And administration of ulinastatin also reduced the incidence of post-ERCP hyperamylasemia （PEHA） （OR, 0.40; 95% C/, 0.28 to 0.58; P〈0.000 01）. Slow infusion of high-dose GM was effective for PEP prevention （OR, 0.44; 95% Cl, 0.25 to 0.79; P=0.006）, and rapid infusion of low-dose GM also showed efficacy for PEP prophylaxis （OR, 0.37; 95% C/, 0.20 to 0.69; P=0.002）. NNT was 7 and 6 respectively. However, administration of GM at low doses and by slow infusions was ineffective （OR, 0.99; 95% Cl, 0.64 to 1.55; P=0.98）. Administration of GM had the tendency to reduce PEHA rate, but not to a statistical significance （OR, 0.86; 95% CI, 0.73 to 1.01; P=0.06）. When low-quality studies were excluded, the meta-analysis with two high-quality studies indicated that ulinastatin did not reduce the rate of PEP （OR, 0.63; 95% Cl, 0.32 to 1.26; P=0.19） and PEHA incidence （OR, 0.80; 95% Cl, 0.31 to 2.07; P=0.64）. The meta-analysis with six high-quality studies showed that GM administration decreased PEP incidence （OR, 0.52; 95% CI, 0.29 to 0.91;
